Drug Trial Radar · NCT05069428
Delirium Reduction With Ramelteon
Last checked: Nov 20, 2026Latest source record: Aug 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
506
Planned (sponsor's estimate)
Start
Mar 26, 2023
Primary completion
Mar 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Centennial Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.
Conditions
- Delirium
Interventions
Ramelteon 8mgDrug
administered crushed, orally at 20:30
Primary outcomes
What the sponsor says the trial is designed to measure.
- Days alive without delirium or coma in the ICUTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centennial Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.